Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Nanocarrier-Mediated PROTAC Delivery for Targeted Oncogenic Protein Degradation in Triple-Negative Breast Cancer
View through CrossRef
anocarriers have shown great potential in the targeted degradation of oncogenic proteins in triple-negative breast cancer (TNBC), offering a promising approach in cancer treatment. PROTACs (Proteolysis Targeting Chimeras) are small molecules designed to degrade specific proteins that are overexpressed or mutated in TNBC. By using nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers, PROTACs can be delivered more effectively to cancer cells, reducing toxicity to healthy cells and enhancing therapeutic outcomes. While research has demonstrated the promise of this strategy, further studies are needed to optimize PROTAC delivery systems and assess their long-term safety and effectiveness in clinical settings. This review outlines recent advances in nanocarrier-based PROTAC delivery for TNBC and discusses future directions in this evolving field.
Title: Nanocarrier-Mediated PROTAC Delivery for Targeted Oncogenic Protein Degradation in Triple-Negative Breast Cancer
Description:
anocarriers have shown great potential in the targeted degradation of oncogenic proteins in triple-negative breast cancer (TNBC), offering a promising approach in cancer treatment.
PROTACs (Proteolysis Targeting Chimeras) are small molecules designed to degrade specific proteins that are overexpressed or mutated in TNBC.
By using nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers, PROTACs can be delivered more effectively to cancer cells, reducing toxicity to healthy cells and enhancing therapeutic outcomes.
While research has demonstrated the promise of this strategy, further studies are needed to optimize PROTAC delivery systems and assess their long-term safety and effectiveness in clinical settings.
This review outlines recent advances in nanocarrier-based PROTAC delivery for TNBC and discusses future directions in this evolving field.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Interpretable PROTAC degradation prediction with structure-informed deep ternary attention framework
Interpretable PROTAC degradation prediction with structure-informed deep ternary attention framework
Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional ligands that form ternary complexes with Protein Of Interests (POIs) and E3 ligases, exploiting the ubiquitin-protea...
Abstract 1685: Overcoming acquired resistance to PROTAC degraders
Abstract 1685: Overcoming acquired resistance to PROTAC degraders
Abstract
Background: Proteolysis-targeting chimera (PROTAC) technology has been widely investigated for cancer treatment and there have been several PROTAC degrader-...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
LM-PROTAC: a language model-driven PROTAC generation pipeline with dual constraints of structure and property
LM-PROTAC: a language model-driven PROTAC generation pipeline with dual constraints of structure and property
Abstract
The imperfect modeling of ternary complexes has limited the application of computer-aided drug discovery tools in PROTAC research and development. In this study, a...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...